Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.
clinical research / practice
infection and infectious agents - viral
infectious disease
kidney transplantation / nephrology
vaccine
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
19
05
2021
received:
22
04
2021
accepted:
21
05
2021
pubmed:
27
5
2021
medline:
11
8
2021
entrez:
26
5
2021
Statut:
ppublish
Résumé
According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and 2 weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with antithymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.
Identifiants
pubmed: 34036720
doi: 10.1111/ajt.16701
pmc: PMC8222867
pii: S1600-6135(22)08672-5
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2727-2739Informations de copyright
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Am J Kidney Dis. 2009 Jul;54(1):112-21
pubmed: 19185404
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Clin Infect Dis. 2011 Jan 15;52(2):248-56
pubmed: 21288852
Clin Infect Dis. 2011 Jan 15;52(2):157-62
pubmed: 21288837
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042
pubmed: 33824157
Am J Transplant. 2020 Nov;20(11):3210-3215
pubmed: 32777178
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Am J Transplant. 2021 Mar;21(3):1295-1303
pubmed: 33259686
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Diabetes Care. 2012 Dec;35(12):2690-7
pubmed: 23173138
Am J Transplant. 2015 Apr;15(4):1028-38
pubmed: 25758660
Hepatogastroenterology. 1997 Jan-Feb;44(13):235-8
pubmed: 9058151
Clin Infect Dis. 2017 Apr 01;64(7):829-838
pubmed: 28362949
Clin Infect Dis. 2018 May 17;66(11):1698-1704
pubmed: 29253089
Kidney Int Rep. 2018 Mar 30;3(4):926-938
pubmed: 29989033
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Am J Transplant. 2020 Oct;20(10):2958-2959
pubmed: 32368838